The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis
Objective Anti–transcription intermediary factor 1γ (anti‐TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti‐TIF1γ–positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2019-08, Vol.71 (8), p.1360-1370 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1370 |
|---|---|
| container_issue | 8 |
| container_start_page | 1360 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 71 |
| creator | Aussy, Audrey Fréret, Manuel Gallay, Laure Bessis, Didier Vincent, Thierry Jullien, Denis Drouot, Laurent Jouen, Fabienne Joly, Pascal Marie, Isabelle Meyer, Alain Sibilia, Jean Bader‐Meunier, Brigitte Hachulla, Eric Hamidou, Mohammed Huë, Sophie Charuel, Jean‐Luc Fabien, Nicole Viailly, Pierre‐Julien Allenbach, Yves Benveniste, Olivier Cordel, Nadège Boyer, Olivier |
| description | Objective
Anti–transcription intermediary factor 1γ (anti‐TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti‐TIF1γ–positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM.
Methods
This multicenter study was conducted in adult anti‐TIF1γ–positive DM patients from August 2013 to August 2017. Anti‐TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model.
Results
Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti‐TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow‐up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti‐TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow‐up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti‐TIF1γ IgG2 (P = 0.048) were independently associated with mortality.
Conclusion
Our findings indicate that anti‐TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti‐TIF1γ–positive DM patients. |
| doi_str_mv | 10.1002/art.40895 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02352134v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2265370203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3875-79f790169a5656523cb448c66d58f123b57cfbe05dcf6e9bf04fd6acaf82cd2c3</originalsourceid><addsrcrecordid>eNp1kU9u1DAUhyMEolXpggsgS2xgMa3_xE6yDANtR5qqEpqurRfHpi4Ze7Cdoux6gy44CvfgEJwED9MWCan2wk_W58_P_hXFa4KPCMb0GEI6KnHd8GfFPmVUzDjF_PlDTRqyVxzGeI3zaCosMH9Z7LHMC1zX-8Xd6kqjxZdTihbRp2mjkTeodcn-vv2xCuCiCnaTrHdo4ZIOa91bCBM6AZV8QOTXT9SOyUM-0Pne6pg1CNAH69cQvuqwtc3BqVyB69G5DwkGmyZkHWr7cUjoY5ZC8uvJR5tsfFW8MDBEfXi_HhSXJ59W87PZ8uJ0MW-XM8Xqis-qxlQNJqIBLvKkTHVlWSshel4bQlnHK2U6jXmvjNBNZ3BpegEKTE1VTxU7KN7vvFcwyE2wud1JerDyrF3K7R6mjFPCyhuS2Xc7dhP8t1HHJNc2Kj0M4LQfo6Sk4VTQkm7Rt_-h134MLr9EUio4qzDF7N_lKvgYgzaPHRAst6HKHKr8G2pm39wbxy7__iP5EGEGjnfAdzvo6WmTbD-vdso_-6msvA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2265370203</pqid></control><display><type>article</type><title>The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Aussy, Audrey ; Fréret, Manuel ; Gallay, Laure ; Bessis, Didier ; Vincent, Thierry ; Jullien, Denis ; Drouot, Laurent ; Jouen, Fabienne ; Joly, Pascal ; Marie, Isabelle ; Meyer, Alain ; Sibilia, Jean ; Bader‐Meunier, Brigitte ; Hachulla, Eric ; Hamidou, Mohammed ; Huë, Sophie ; Charuel, Jean‐Luc ; Fabien, Nicole ; Viailly, Pierre‐Julien ; Allenbach, Yves ; Benveniste, Olivier ; Cordel, Nadège ; Boyer, Olivier</creator><creatorcontrib>Aussy, Audrey ; Fréret, Manuel ; Gallay, Laure ; Bessis, Didier ; Vincent, Thierry ; Jullien, Denis ; Drouot, Laurent ; Jouen, Fabienne ; Joly, Pascal ; Marie, Isabelle ; Meyer, Alain ; Sibilia, Jean ; Bader‐Meunier, Brigitte ; Hachulla, Eric ; Hamidou, Mohammed ; Huë, Sophie ; Charuel, Jean‐Luc ; Fabien, Nicole ; Viailly, Pierre‐Julien ; Allenbach, Yves ; Benveniste, Olivier ; Cordel, Nadège ; Boyer, Olivier ; OncoMyositis Study Group ; the OncoMyositis Study Group</creatorcontrib><description>Objective
Anti–transcription intermediary factor 1γ (anti‐TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti‐TIF1γ–positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM.
Methods
This multicenter study was conducted in adult anti‐TIF1γ–positive DM patients from August 2013 to August 2017. Anti‐TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model.
Results
Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti‐TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow‐up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti‐TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow‐up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti‐TIF1γ IgG2 (P = 0.048) were independently associated with mortality.
Conclusion
Our findings indicate that anti‐TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti‐TIF1γ–positive DM patients.</description><identifier>ISSN: 2326-5191</identifier><identifier>ISSN: 2326-5205</identifier><identifier>EISSN: 2326-5205</identifier><identifier>EISSN: 2326-5191</identifier><identifier>DOI: 10.1002/art.40895</identifier><identifier>PMID: 30896088</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Age ; Aged ; Antibodies ; Autoantibodies ; Autoantibodies - blood ; Autoantibodies - immunology ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - immunology ; Cancer ; Creatine ; Creatine kinase ; Dermatomyositis ; Dermatomyositis - blood ; Dermatomyositis - immunology ; Dermatomyositis - mortality ; Female ; Fluorescence ; Hazards ; Health risks ; Humans ; Immunoassay ; Immunoglobulin G ; Immunoglobulin G - immunology ; Kinases ; Life Sciences ; Male ; Malignancy ; Men ; Middle Aged ; Mortality ; Multivariate Analysis ; Neoplasms - blood ; Neoplasms - immunology ; Proportional Hazards Models ; Regression analysis ; Regression models ; Retrospective Studies ; Risk analysis ; Risk Assessment ; Risk Factors ; Sex ; Survival ; Transcription Factors - immunology</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2019-08, Vol.71 (8), p.1360-1370</ispartof><rights>2019, American College of Rheumatology</rights><rights>2019, American College of Rheumatology.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3875-79f790169a5656523cb448c66d58f123b57cfbe05dcf6e9bf04fd6acaf82cd2c3</citedby><cites>FETCH-LOGICAL-c3875-79f790169a5656523cb448c66d58f123b57cfbe05dcf6e9bf04fd6acaf82cd2c3</cites><orcidid>0000-0002-7591-307X ; 0000-0002-3432-6223 ; 0000-0002-1167-5797 ; 0000-0001-7432-847X ; 0000-0002-7020-1954 ; 0000-0002-3185-7993 ; 0000-0003-2879-9304 ; 0000-0002-2530-7346 ; 0000-0003-1679-8005</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.40895$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.40895$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30896088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02352134$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Aussy, Audrey</creatorcontrib><creatorcontrib>Fréret, Manuel</creatorcontrib><creatorcontrib>Gallay, Laure</creatorcontrib><creatorcontrib>Bessis, Didier</creatorcontrib><creatorcontrib>Vincent, Thierry</creatorcontrib><creatorcontrib>Jullien, Denis</creatorcontrib><creatorcontrib>Drouot, Laurent</creatorcontrib><creatorcontrib>Jouen, Fabienne</creatorcontrib><creatorcontrib>Joly, Pascal</creatorcontrib><creatorcontrib>Marie, Isabelle</creatorcontrib><creatorcontrib>Meyer, Alain</creatorcontrib><creatorcontrib>Sibilia, Jean</creatorcontrib><creatorcontrib>Bader‐Meunier, Brigitte</creatorcontrib><creatorcontrib>Hachulla, Eric</creatorcontrib><creatorcontrib>Hamidou, Mohammed</creatorcontrib><creatorcontrib>Huë, Sophie</creatorcontrib><creatorcontrib>Charuel, Jean‐Luc</creatorcontrib><creatorcontrib>Fabien, Nicole</creatorcontrib><creatorcontrib>Viailly, Pierre‐Julien</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Cordel, Nadège</creatorcontrib><creatorcontrib>Boyer, Olivier</creatorcontrib><creatorcontrib>OncoMyositis Study Group</creatorcontrib><creatorcontrib>the OncoMyositis Study Group</creatorcontrib><title>The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
Anti–transcription intermediary factor 1γ (anti‐TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti‐TIF1γ–positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM.
Methods
This multicenter study was conducted in adult anti‐TIF1γ–positive DM patients from August 2013 to August 2017. Anti‐TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model.
Results
Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti‐TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow‐up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti‐TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow‐up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti‐TIF1γ IgG2 (P = 0.048) were independently associated with mortality.
Conclusion
Our findings indicate that anti‐TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti‐TIF1γ–positive DM patients.</description><subject>Age</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Autoantibodies - blood</subject><subject>Autoantibodies - immunology</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Cancer</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Dermatomyositis</subject><subject>Dermatomyositis - blood</subject><subject>Dermatomyositis - immunology</subject><subject>Dermatomyositis - mortality</subject><subject>Female</subject><subject>Fluorescence</subject><subject>Hazards</subject><subject>Health risks</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - immunology</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Malignancy</subject><subject>Men</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - immunology</subject><subject>Proportional Hazards Models</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Sex</subject><subject>Survival</subject><subject>Transcription Factors - immunology</subject><issn>2326-5191</issn><issn>2326-5205</issn><issn>2326-5205</issn><issn>2326-5191</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9u1DAUhyMEolXpggsgS2xgMa3_xE6yDANtR5qqEpqurRfHpi4Ze7Cdoux6gy44CvfgEJwED9MWCan2wk_W58_P_hXFa4KPCMb0GEI6KnHd8GfFPmVUzDjF_PlDTRqyVxzGeI3zaCosMH9Z7LHMC1zX-8Xd6kqjxZdTihbRp2mjkTeodcn-vv2xCuCiCnaTrHdo4ZIOa91bCBM6AZV8QOTXT9SOyUM-0Pne6pg1CNAH69cQvuqwtc3BqVyB69G5DwkGmyZkHWr7cUjoY5ZC8uvJR5tsfFW8MDBEfXi_HhSXJ59W87PZ8uJ0MW-XM8Xqis-qxlQNJqIBLvKkTHVlWSshel4bQlnHK2U6jXmvjNBNZ3BpegEKTE1VTxU7KN7vvFcwyE2wud1JerDyrF3K7R6mjFPCyhuS2Xc7dhP8t1HHJNc2Kj0M4LQfo6Sk4VTQkm7Rt_-h134MLr9EUio4qzDF7N_lKvgYgzaPHRAst6HKHKr8G2pm39wbxy7__iP5EGEGjnfAdzvo6WmTbD-vdso_-6msvA</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Aussy, Audrey</creator><creator>Fréret, Manuel</creator><creator>Gallay, Laure</creator><creator>Bessis, Didier</creator><creator>Vincent, Thierry</creator><creator>Jullien, Denis</creator><creator>Drouot, Laurent</creator><creator>Jouen, Fabienne</creator><creator>Joly, Pascal</creator><creator>Marie, Isabelle</creator><creator>Meyer, Alain</creator><creator>Sibilia, Jean</creator><creator>Bader‐Meunier, Brigitte</creator><creator>Hachulla, Eric</creator><creator>Hamidou, Mohammed</creator><creator>Huë, Sophie</creator><creator>Charuel, Jean‐Luc</creator><creator>Fabien, Nicole</creator><creator>Viailly, Pierre‐Julien</creator><creator>Allenbach, Yves</creator><creator>Benveniste, Olivier</creator><creator>Cordel, Nadège</creator><creator>Boyer, Olivier</creator><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-7591-307X</orcidid><orcidid>https://orcid.org/0000-0002-3432-6223</orcidid><orcidid>https://orcid.org/0000-0002-1167-5797</orcidid><orcidid>https://orcid.org/0000-0001-7432-847X</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-3185-7993</orcidid><orcidid>https://orcid.org/0000-0003-2879-9304</orcidid><orcidid>https://orcid.org/0000-0002-2530-7346</orcidid><orcidid>https://orcid.org/0000-0003-1679-8005</orcidid></search><sort><creationdate>201908</creationdate><title>The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis</title><author>Aussy, Audrey ; Fréret, Manuel ; Gallay, Laure ; Bessis, Didier ; Vincent, Thierry ; Jullien, Denis ; Drouot, Laurent ; Jouen, Fabienne ; Joly, Pascal ; Marie, Isabelle ; Meyer, Alain ; Sibilia, Jean ; Bader‐Meunier, Brigitte ; Hachulla, Eric ; Hamidou, Mohammed ; Huë, Sophie ; Charuel, Jean‐Luc ; Fabien, Nicole ; Viailly, Pierre‐Julien ; Allenbach, Yves ; Benveniste, Olivier ; Cordel, Nadège ; Boyer, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3875-79f790169a5656523cb448c66d58f123b57cfbe05dcf6e9bf04fd6acaf82cd2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Autoantibodies - blood</topic><topic>Autoantibodies - immunology</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Cancer</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Dermatomyositis</topic><topic>Dermatomyositis - blood</topic><topic>Dermatomyositis - immunology</topic><topic>Dermatomyositis - mortality</topic><topic>Female</topic><topic>Fluorescence</topic><topic>Hazards</topic><topic>Health risks</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - immunology</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Malignancy</topic><topic>Men</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - immunology</topic><topic>Proportional Hazards Models</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Sex</topic><topic>Survival</topic><topic>Transcription Factors - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aussy, Audrey</creatorcontrib><creatorcontrib>Fréret, Manuel</creatorcontrib><creatorcontrib>Gallay, Laure</creatorcontrib><creatorcontrib>Bessis, Didier</creatorcontrib><creatorcontrib>Vincent, Thierry</creatorcontrib><creatorcontrib>Jullien, Denis</creatorcontrib><creatorcontrib>Drouot, Laurent</creatorcontrib><creatorcontrib>Jouen, Fabienne</creatorcontrib><creatorcontrib>Joly, Pascal</creatorcontrib><creatorcontrib>Marie, Isabelle</creatorcontrib><creatorcontrib>Meyer, Alain</creatorcontrib><creatorcontrib>Sibilia, Jean</creatorcontrib><creatorcontrib>Bader‐Meunier, Brigitte</creatorcontrib><creatorcontrib>Hachulla, Eric</creatorcontrib><creatorcontrib>Hamidou, Mohammed</creatorcontrib><creatorcontrib>Huë, Sophie</creatorcontrib><creatorcontrib>Charuel, Jean‐Luc</creatorcontrib><creatorcontrib>Fabien, Nicole</creatorcontrib><creatorcontrib>Viailly, Pierre‐Julien</creatorcontrib><creatorcontrib>Allenbach, Yves</creatorcontrib><creatorcontrib>Benveniste, Olivier</creatorcontrib><creatorcontrib>Cordel, Nadège</creatorcontrib><creatorcontrib>Boyer, Olivier</creatorcontrib><creatorcontrib>OncoMyositis Study Group</creatorcontrib><creatorcontrib>the OncoMyositis Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aussy, Audrey</au><au>Fréret, Manuel</au><au>Gallay, Laure</au><au>Bessis, Didier</au><au>Vincent, Thierry</au><au>Jullien, Denis</au><au>Drouot, Laurent</au><au>Jouen, Fabienne</au><au>Joly, Pascal</au><au>Marie, Isabelle</au><au>Meyer, Alain</au><au>Sibilia, Jean</au><au>Bader‐Meunier, Brigitte</au><au>Hachulla, Eric</au><au>Hamidou, Mohammed</au><au>Huë, Sophie</au><au>Charuel, Jean‐Luc</au><au>Fabien, Nicole</au><au>Viailly, Pierre‐Julien</au><au>Allenbach, Yves</au><au>Benveniste, Olivier</au><au>Cordel, Nadège</au><au>Boyer, Olivier</au><aucorp>OncoMyositis Study Group</aucorp><aucorp>the OncoMyositis Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2019-08</date><risdate>2019</risdate><volume>71</volume><issue>8</issue><spage>1360</spage><epage>1370</epage><pages>1360-1370</pages><issn>2326-5191</issn><issn>2326-5205</issn><eissn>2326-5205</eissn><eissn>2326-5191</eissn><abstract>Objective
Anti–transcription intermediary factor 1γ (anti‐TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti‐TIF1γ–positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM.
Methods
This multicenter study was conducted in adult anti‐TIF1γ–positive DM patients from August 2013 to August 2017. Anti‐TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model.
Results
Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti‐TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow‐up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti‐TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow‐up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti‐TIF1γ IgG2 (P = 0.048) were independently associated with mortality.
Conclusion
Our findings indicate that anti‐TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti‐TIF1γ–positive DM patients.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30896088</pmid><doi>10.1002/art.40895</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7591-307X</orcidid><orcidid>https://orcid.org/0000-0002-3432-6223</orcidid><orcidid>https://orcid.org/0000-0002-1167-5797</orcidid><orcidid>https://orcid.org/0000-0001-7432-847X</orcidid><orcidid>https://orcid.org/0000-0002-7020-1954</orcidid><orcidid>https://orcid.org/0000-0002-3185-7993</orcidid><orcidid>https://orcid.org/0000-0003-2879-9304</orcidid><orcidid>https://orcid.org/0000-0002-2530-7346</orcidid><orcidid>https://orcid.org/0000-0003-1679-8005</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2019-08, Vol.71 (8), p.1360-1370 |
| issn | 2326-5191 2326-5205 2326-5205 2326-5191 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02352134v1 |
| source | Wiley-Blackwell Journals; MEDLINE; Alma/SFX Local Collection |
| subjects | Age Aged Antibodies Autoantibodies Autoantibodies - blood Autoantibodies - immunology Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - immunology Cancer Creatine Creatine kinase Dermatomyositis Dermatomyositis - blood Dermatomyositis - immunology Dermatomyositis - mortality Female Fluorescence Hazards Health risks Humans Immunoassay Immunoglobulin G Immunoglobulin G - immunology Kinases Life Sciences Male Malignancy Men Middle Aged Mortality Multivariate Analysis Neoplasms - blood Neoplasms - immunology Proportional Hazards Models Regression analysis Regression models Retrospective Studies Risk analysis Risk Assessment Risk Factors Sex Survival Transcription Factors - immunology |
| title | The IgG2 Isotype of Anti–Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A50%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20IgG2%20Isotype%20of%20Anti%E2%80%93Transcription%20Intermediary%20Factor%201%CE%B3%20Autoantibodies%20Is%20a%20Biomarker%20of%20Cancer%20and%20Mortality%20in%20Adult%20Dermatomyositis&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Aussy,%20Audrey&rft.aucorp=OncoMyositis%20Study%20Group&rft.date=2019-08&rft.volume=71&rft.issue=8&rft.spage=1360&rft.epage=1370&rft.pages=1360-1370&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.40895&rft_dat=%3Cproquest_hal_p%3E2265370203%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2265370203&rft_id=info:pmid/30896088&rfr_iscdi=true |